Phenominer Database Results (18 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 108.0 % 4.0 14.97 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107089 3073
GK/Jpe logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 -5.87 null 0.07 0.19 tissue force analysis utilizing a force transducer 0.0 0 109095 3108
GK/Jpe acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 45.0 % 2.2 5.82 tissue force analysis utilizing a force transducer 0.0 0 109100 3108
GK/Jpe sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 99.6 % 0.01 0.03 tissue force analysis utilizing a force transducer 0.0 0 109110 3108
GK/Jpe logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 -6.4 null 0.03 0.08 tissue force analysis utilizing a force transducer 0.0 0 109105 3108
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 119.0 nmol/l 15.0 56.12 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107299 3073
SHRSP/A3NCrl concentration of BAY 60-4552 at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 75.0 nmol/l 16.0 59.87 tissue force analysis utilizing a force transducer 0.0 0 standard rat chow 107306 3073
SHRSP/A3NCrl concentration of GSK2181236A at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 270.0 nmol/l 70.0 261.92 tissue force analysis utilizing a force transducer 0.0 0 standard rat chow 107310 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 14 0.07 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107077 3073
W/Jpe sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 99.9 % 0.1 0.26 tissue force analysis utilizing a force transducer 0.0 0 wistar 109109 3108
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 85.0 % 3.0 11.22 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107293 3073
W/Jpe acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 78.5 % 3.1 8.2 tissue force analysis utilizing a force transducer 0.0 0 wistar 109099 3108
W/Jpe logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 -5.87 null 0.04 0.11 tissue force analysis utilizing a force transducer 0.0 0 wistar 109104 3108
SHRSP/A3NCrl BAY 60-4552-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 110.0 % 2.0 7.48 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107308 3073
SHRSP/A3NCrl GSK2181236A-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 110.0 % 3.0 11.22 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107312 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 0.05 10E-7mol/l 0.01 0.04 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107083 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 14 90.0 % 4.0 14.97 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107071 3073
W/Jpe logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) control condition Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. vasodilation trait male 540 days 7 -6.85 null 0.1 0.26 tissue force analysis utilizing a force transducer 0.0 0 wistar 109094 3108